Mesoblast Limited (MESO)
NASDAQ: MESO · IEX Real-Time Price · USD
+0.33 (4.70%)
May 17, 2024, 4:00 PM EDT - Market closed

Mesoblast Revenue

Mesoblast had revenue of $7.25M in the twelve months ending December 31, 2023, down -10.69% year-over-year. In the fiscal year ending June 30, 2023, Mesoblast had annual revenue of $7.50M, a decrease of -26.54%.

Revenue (ttm)
Revenue Growth
P/S Ratio
Revenue / Employee
Market Cap
780.86M USD

Revenue Chart


Fiscal Year End Revenue Change Growth
Jun 30, 20237.50M-2.71M-26.54%
Jun 30, 202210.21M2.78M37.36%
Jun 30, 20217.43M-24.72M-76.88%
Jun 30, 202032.16M15.43M92.30%
Jun 30, 201916.72M-619.00K-3.57%
Jun 30, 201817.34M14.93M618.95%
Jun 30, 20172.41M-40.14M-94.33%
Jun 30, 201642.55M22.79M115.31%
Jun 30, 201519.76M-3.63M-15.52%
Jun 30, 201423.39M-5.91M-20.17%
Jun 30, 201329.30M--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Healthcare Services Group 1.68B
Embecta 1.13B
HealthStream 282.88M
Evolus 219.70M
Aurinia Pharmaceuticals 191.41M
Atrion 176.67M
Viridian Therapeutics 288.00K
Revenue Rankings